Atara Biotherapeutics Submits Tabelecleucel BLA For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S. FDA; Acceptance Of BLA Will Trigger $20M Milestone Payment From Pierre Fabre Laboratories, With Potential For Additional $60M Milestone Upon FDA Approval
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics has submitted a Biologics License Application (BLA) to the FDA for tabelecleucel (tab-cel®) for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Acceptance of the BLA will trigger a $20 million milestone payment from Pierre Fabre Laboratories, with an additional $60 million possible upon FDA approval.
May 20, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atara Biotherapeutics has submitted a BLA to the FDA for tabelecleucel (tab-cel®) for treating EBV+ PTLD. Acceptance of the BLA will trigger a $20 million milestone payment from Pierre Fabre Laboratories, with an additional $60 million possible upon FDA approval.
The submission of the BLA is a significant regulatory milestone for Atara Biotherapeutics. If the BLA is accepted, it will trigger a $20 million milestone payment, providing immediate financial benefit. Additionally, FDA approval could lead to a further $60 million payment, enhancing the company's revenue and financial stability. This news is likely to positively impact ATRA's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100